arthritis-research.com

Table 6
Cardio-renal adverse events reported in studies of patients treated for arthritis
			Number of		Incidence of events (%)

Outcome/ comparisons	Celecoxib daily dose	Comparator and daily dose	Trials	Patients	Celecoxib	Comparator	Relative risk^a(95% CI)	NNTp^bor NNH^c(95% CI)

*Myocardial infarction*
Celecoxib v placebo	Any	Placebo	16	9,315	0.12	0.07		10 events
Celecoxib v paracetamol	Any	Paracetamol 4,000 mg	2	1,056	0.00	0.00		0 events
Celecoxib v rofecoxib	Any	Rofecoxib 25 mg	5	2,667	0.00	0.08		1 event
Celecoxib (200/400) v NSAID	200–400 mg	NSAID to maximum daily	16	21,818	0.15	0.04	1.9 (0.87–4.1)	23 events
Celecoxib (any dose) v NSAID	Any	NSAID to maximum daily	17	30,220	0.22	0.14	1.6 (0.93–2.6)	56 events
Celecoxib (any dose) v any active	Any	Any active comparator	23	34,174	0.19	0.13	1.4 (0.87–2.3)	57 events
Celecoxib (any dose) v any comparator	Any	Any comparator	30	38,499	0.18	0.12	1.4 (0.88–2.2)	59 events
Celecoxib (any dose) v noncoxib comparator	Any	Any noncoxib comparator	28	36,316	0.19	0.12	1.4 (0.88–2.2)	57 events

*Cardiac failure*

Celecoxib v placebo	Any	Placebo	16	9,834	0.06	0.03		5 events
Celecoxib v paracetamol	Any	Paracetamol 4,000 mg	2	1,056	0.00	0.00		0 events
Celecoxib v rofecoxib	Any	Rofecoxib 25 mg	5	2,671	0.15	0.60		10 events
Celecoxib (200/400) v NSAID	200–400 mg	NSAID to maximum daily	15	21,859	0.06	0.15	0.54 (0.29–1.02)	21 events
Celecoxib (any dose) v NSAID	Any	NSAID to maximum daily	17	30,917	0.11	0.20	0.70 (0.43–1.1)	45 events
Celecoxib (any dose) v any active	Any	Any active comparator	23	34,512	0.11	0.23	0.64 (0.41–1.0)	55 events

*Raised creatinine (above 1.3 × upper limit of normal)*

Celecoxib v placebo	Any	Placebo	5	2,776	1.3	0.7	1.65 (0.69–4.0)
Celecoxib v paracetamol	Any	Paracetamol 4,000 mg
Celecoxib v rofecoxib	Any	Rofecoxib 25 mg
Celecoxib (200/400) v NSAID	200–400 mg	NSAID to maximum daily	9	15,319	0.3	0.5	0.78 (0.46–1.3)
Celecoxib (any dose) v NSAID	Any	NSAID to maximum daily
Celecoxib (any dose) v any active	Any	Any active comparator	10	15,657	0.3	0.5	0.79 (0.47–1.3)

*Hypertension and aggravated hypertension*

Celecoxib v placebo	Any	Placebo	16	9,321	1.0	0.6	1.4 (0.85–2.4)
Celecoxib v paracetamol	Any	Paracetamol 4,000 mg	2	1,056	0.2	0.6		4 events
Celecoxib v rofecoxib	Any	Rofecoxib 25 mg	5	2,671	3.5	4.6	0.75 (0.52–1.1)
Celecoxib (200/400) v NSAID	200–400 mg	NSAID to maximum daily	16	22,518	1.3	1.4	0.92 (0.73–1.2)
Celecoxib (any dose) v NSAID	Any	NSAID to maximum daily	17	30,921	1.6	1.6	1.1 (0.90–1.3)
Celecoxib (any dose) v any active	Any	Any active comparator	23	34,512	1.7	1.8	1.0 (0.86–1.2)

*Oedema at any site*

Celecoxib v placebo	Any	Placebo	16	9,321	2.6	1.4	1.9 (1.4–2.7)	79 (54–145)^c
Celecoxib v paracetamol	Any	Paracetamol 4,000 mg	2	1,056	2.3	1.8	1.3 (0.56–3.0)
Celecoxib v rofecoxib	Any	Rofecoxib 25 mg	5	2,671	18.0	25.0	0.72 (0.62–0.83)	14 (10–25)^b
Celecoxib (200/400) v NSAID	200–400 mg	NSAID to maximum daily	16	21,825	2.4	2.5	0.98 (0.82–1.2)
Celecoxib (any dose) v NSAID	Any	NSAID to maximum daily	17	30,921	2.9	3.5	0.92 (0.81–1.05)
Celecoxib (any dose) v any active	Any	Any active comparator	23	34,512	3.8	5.4	0.84 (0.76–0.92)	62 (48–87)^b

^aRelative risk: bold indicates statistically significant difference. ^bNNTp (number-needed-to-treat to prevent one event) is indicated by bold. ^cNNH (number-needed-to-treat to harm one patient; CI, confidence interval; NSAID, nonsteroidal anti-inflammatory drug.
Moore et al. Arthritis Research & Therapy 2005 7:R644 doi:10.1186/ar1704

Table 6